- Aliro****ab, sold
under the
brand name
Praluent, is a
medication used as a second-line
treatment for high
cholesterol for
adults whose cholesterol is not...
- used for
metastatic colorectal cancer approved by the FDA in
August 2012.
Praluent (aliro****ab) is
indicated as an
adjunct to diet and
maximally tolerated...
-
Bloomfield D,
Decker S (5
January 2017). "Amgen Wins Ban on Sanofi's
Praluent Cholesterol Drug Sales".
Bloomberg News. "Amgen Inc. V. Sanofi". SCOTUSblog...
-
February 2019). "PCSK9 price-cut
matchup is on, as
Regeneron and
Sanofi slash Praluent list tag 60%".
Fierce Pharma. Questex.
Retrieved 2019-05-18. Hall SS (April...
-
humanized CD52 B-cell
chronic lymphocytic leukemia 103948 Link aliro****ab
Praluent Sanofi Aventis 7/24/2015
subcutaneous fully human PCSK9
Heterozygous familial...
-
Alemtuzumab Lemtrada,
Campath mab
humanized CD52 Y
multiple sclerosis Aliro****ab
Praluent mab
human PCSK9 Y
hypercholesterolemia Altumomab pentetate Hybri-ceaker...
- (Clopidogrel), for atherothrombosis,
marketed by Bristol-Myers Squibb.
Praluent (Aliro****ab), for
heterozygous familial hypercholesterolemia and clinical...
- Bibcode:2013Natur.496..152H, doi:10.1038/496152a, PMID 23579660 FDA
approves Praluent to
treat certain patients with high cholesterol, FDA, 24 July 2015, retrieved...
